The Functional Observational Battery (FOB) is a neurotoxicity screening assay composed of 25-30 descriptive, scalar, binary, and continuous endpoints. These outcomes have been grouped into six biologically logical domains as a means to interpret the neuroactive properties of tested chemicals (V. C. Moser, 1992, /. Am. Coll. Toxicol. 10(6), 661-669). However, no data-based exploration of these functional domains has been done. We investigated the degree to which experimental data correspond to the domain group-, ings by examining severity scores from 10 chemicals tested using a standardized protocol for acute exposure (V. C. Moser et at, 1995, /. Toxicol Environ. Health 45, 173-210) and identifying endpoint groupings (factors) that best describe the interrelationships in the data, allowing a statistical assessment of whether the FOB endpoints break into domains. We also used a standard measure of bivariate association to confirm the results of the factor analysis. Our results show that while there are clear relationships among variables that compose some domains, there is often substantial correlation among endpoints in different domains. In addition, we investigated a related issue concerning the relative power of the chosen endpoint groupings for identifying significant domain effects. Results from a randomization analysis of the 10 chemicals suggest that the neurophysiologic domain structuring may provide some degree of statistical efficiency for identifying effects.
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The goal of a neurotoxicity screening process is to identify chemicals that are neurotoxic hazards. The U.S. EPA Neurotoxicity Testing Guidelines (1991) , developed in the Office of Pesticide Programs and the Office of Toxic Substances, describe three distinct evaluations that compose the first tier of the screening battery: an automated measure of motor activity (MA), a Functional Observational Battery (FOB) to assess behavioral and neurologic function in the rat, and a neuropathologic examination following euthanization. Additional tiers would include tests of scheduled controlled operant behavior, and tests to determine the dose-response relationship and the mechanism of action. Although these subsequent tests are recommended, in practice the results of the FOB, MA, and neuropathology tests compose the core of data now available for evaluating the neurotoxicity of chemicals.
The FOB typically consists of 25-30 endpoints measured at several (usually three) time points (Moser et al., 1988) (Table 1) . While a large number of endpoints are thought to be needed to encompass a wide spectrum of neurologic effects measured as behavioral responses, it is possible that some of the endpoints are measuring similar neurologic effects and thus are redundant. Moreover, in the analysis of data with such a large number of endpoints, failure to account for multiplicity may lead to false positive results (type I error). On the other hand, use of some multiplicity correction procedures (such as Bonferroni) may be very conservative and have low statistical power, leading to possible false negatives, an undesirable feature in a screening assay. If an underlying correlation structure existed in the data, it could be exploited to increase statistical efficiency by decreasing the number of endpoints for comparison. Recently, such a structure was proposed by Moser (1992) where the FOB endpoints were grouped into six neurophysiologically based functional domains. If endpoints can be grouped into domains, the analysis of domain groupings for neurotoxicity identification may maintain a proper type I error rate, while retaining a low false negative rate and thus increase efficiency for identifying true effects. However, if endpoint groupings are inappropriate, averaging responses within a domain could have a dilutional effect on the outcomes and decrease the ability to identify true effects in a domain-level analysis.
This paper presents an evaluation of the statistical properties of the FOB data and the analysis method proposed by Moser (1992) , not a new FOB data analysis method. The goal of this analysis is to address the question of whether there is statistical support for grouping the endpoints of the FOB into neurophysiologic domains as a means to identify neurotoxic effects of exposure and to increase statistical efficiency. The validity of the grouping of endpoints into do- " R, rank; C, continuous; D, descriptive; Q, quanlal. * The motor activity endpoint has been incorporated into the domain structure with the FOB endpoints to avoid giving it disproportional weight mains is a prerequisite for incorporation of an efficient statistical methodology into the neurologic response data evaluation paradigm. Two evaluation strategies were employed using data on 10 chemicals tested in an acute neurotoxicity screening battery (Moser el ai, 1995) . First, the underlying correlation structure was examined by assessing pairwise associations among the assay endpoints to explore the extent of possible redundancy in the FOB. This procedure allowed investigation of the degree of dependence between the endpoints both within a particular domain and across domains. Determining the extent of dependence between endpoints is important both for the current statistical methods (Creason, 1989) and for the development of any potential multivariate model for the FOB.
The second strategy explored the extent to which the neurophysiologic domains as described by Moser (1992) actually represent a smaller subset of neurologic categories. This was accomplished using two methods. Factor analysis was used to explore both the underlying correlation structure and the variability of the data by statistically grouping the endpoints into factors that best explain overall variability and comparing these statistical groupings to the physiologically based domains. The second method investigated the ability of neurophysiologic domains to identify significant dose-related effects. This was accomplished by comparing the Moser domain structure to a distribution of results obtained by randomly regrouping endpoints. The logic underlying this latter analysis is that if the underlying associations between endpoints represent neurophysiologic domains well, they should on average identify significant dose-related effects better than randomly grouped endpoints in neuroactive domains.
The statistical issues raised in the analysis of multivariate data such as the FOB are common in noncancer hazard identification. Many endpoints need to be measured to gain an understanding of the toxicity of chemicals acting on multiple systems, through different mechanisms. Thus, our evaluation of the methodology that has been proposed by Moser may have applicability in other areas of risk assessment involving multivariate data.
METHODS

Data.
Functional observational battery and motor activity responses in rats after acute exposure to I of 10 chemicals were analyzed in this study. Pretreatment, 4-hr, and 24-hr measurements were obtained for each animal for 22 endpoints measuring neurophysiologic function (Table 1A) . The physiologic measures, body weight, body temperature, and piloerection, were not included in this data set (Table IB) . These data were generously provided by Dr. Virginia C. Moser. The 10 chemicals used in this analysis were originally selected for testing due to their common presence at Superfund sites and lack of systematically measured neurotoxicity data. The chemicals, representing pesticides, industrial chemicals, and solvents, are listed in Table 2 along with a summary of their expected effects in humans and proposed mechanism of action. FOB and MA results for these chemicals are reported in Moser et at (1995) . Each experiment had a control group and four concentrations of chemical with 8 animals per group for a total of 40 animals per experiment Conversion of raw data to severity scores. FOB data consist of continuous, descriptive, count, and binary variables. Since the multiple data types complicate the statistical analysis, a transformation of the data was used to allow for analysis of the entire data set on the same quantitative scale. Data were converted to corresponding severity scores, on a scale of 1 to 4, by the method of Moser (1992) (Table 3 ). The continuous data are converted based on the distance in standard deviation (SD) units from the control mean, while the descriptive endpoints are converted based on their relation to the mode of the control distribution. Objective conversion rules have been developed and the severity score-transformed data have an intuitive interpretation. Moreover, standardization of the data to the control response at each response time point is thought to increase the homogeneity of the responses across time both within a single study and across multiple studies.
Data analysis method under evaluation.
The FOB data analysis method evaluated here was originally proposed by Moser (1992) . The general scheme consists of converting data for each endpoint into severity Curley and Garrettson (1969) , Morgan (1989), and Ecobichon (1996) No human data are available; therefore, effects are reported for rats. Hyperactivity, increased motor activity, stereotypic behavior increased locomotion and rearing Crofton et al. (1989) No neurotoxic effects reported in humans. "Lowest toxicity class in industry." Clayton and Clayton (1981) CNS depression may be seen with ingestion of large amounts. Gosselm (1984) Headache, "disturbance of consciousness,"fleeting excitement and confusion, spasms, tremor, coma, CNS depression, transient CNS stimulation followed by depression. Kim et aL (1994) , Spiller el al. (1993) , Soares and Tift (1982), and ACGIH (1991) Limited human data available: dizziness, headache, fatigue, confusion, altered mental status, delirium, seizures, coma Amnesia, incoherent speech, ataxia intention tremor, positive Rhomberg sign. CNS depression. HSDB (1995) Euphoria, irritability, sluggishness, sleepiness, lightheadedness, dizziness. Headache, impaired concentration and coordination, loss of balance, irritated eyes, nose, and throat, nausea, flushing, confusion, slurred speech. Impaired sensory function (visual and auditory), impaired psychomotor performance. CNS depression. Hall and Rumack (1990) , ATSDR (1993) , ACGIH (1991) , and HSDB (1995) Eye irritation, altered neurobehavioral performance, incoordination, headache. Dizziness, vertigo, lightheadedness, sleepiness, ataxia. CNS depression, coma, peripheral neuropathies, seizures. Rao el aL (1993) , Reichert (1983), and HSDB (1995) Lethargy, fatigue, dizziness, drowsiness, headache, lightheadedness, blurred vision, altered visual perception. Confusion, nausea, vomiting, malaise, restlessness, impaired concentration, irritability, CNS depression, altered visual perception. Kostrzewski et al. (1993) , Davidson and Beliles (1991) , Landrigan et al. (1987) , ACGIH (1991), and HSDB (1995) Acetylcholinesterase inhibition-reversible Increased acetylcholine at the neuromuscular junction of skeletal and smooth muscle and secretory glands with initial increased stimulation of the acetylcholine receptors, followed by receptor densitization. Impaired neuronal transmission. Compound does not penetrate the CNS well. Cranmer (1986) and Ecobichon (1996) Decreased uptake of Cl" via GABA A receptormediated complex, leading to a chloride-induced increase in the resting membrane potential of neurons with GABA-regulated chloride channels. Also inhibits Na + , K + -ATPase and Ca :+ , Mg 1 *-ATPase interfering with calcium transport across the synaptic membranes, resulting in neuronal hyperexcitability. Bloomquist et al. (1986) , Gam et al (1987), and Ecobichon (1996) Indirect dopamine agonist Crofton elaL (1989) None reported.
The mechaniim of action is not well understood.
However, phenol appears to be acting on ti>e central nervous system, possibly through increased monoamine release leading to stimulation or dirough a presynaptic influence to increase acetycholine release. Suziki and Kisara (1985) Unknown. Possibly lipid membrane changes. " Human effects from the toxicologic literature were associated with domains as described by Moser (1992) . The domains of expected effect were assigned a range of scores from + ++, for most likely to be affected at low doses, to '-,' for unlikely to be affected even at high doses. Greater than 2 SD of control group mean Typically seen in untreated rats. Slightly atypical; can be seen occasionally in untreated rats but could be a subtle sign of toxicity. Somewhat atypical; could rarely be seen in untreated rats; would usually reflect moderate intoxication. Completely atypical; reflect marked intoxication.
•From Moser (1992) .
scores; the scores for each endpoint within a domain are then averaged according to the groupings outlined in Table 1 . The resulting six separate domain severity scores for each animal are then analyzed using a repeated measures ANOVA to assess effects of time and exposure level. Once the positive (significant by ANOVA) domains are identified, the individual measures within that domain are analyzed separately using the methods described by Creason (1989) .
Pretreatment adjusted data. Traditionally in behavioral research each animal is used as its own control, a practice designed to decrease the overall group variability and increase the sensitivity of the analysis by controlling for animals whose normal response range may vary widely. Because severity score-transformed data are used for the analysis, two methods exist for calculating the difference between the pretreatment response and the response after treatment The first method is to subtract an animal's pretreatment severity score from its treated severity score. The second method involves subtracting the raw data values, pretreated from the treated, and then transforming the resulting values using a slightly modified severity score transformation. The advantage of the first method, in addition to its simplicity, is that the values are all on the same scale and descriptive variables do not need reinterpretation. Furthermore, descriptive measures may not be amenable to arithmetic calculations, a requirement of the second approach. Thus the first approach was the method employed in our analysis.
Bivariate associations. The gamma measure of association due to Goodman and Kruskal (1979) is a standard measure of association among two ordinal variables and has a simple interpretation. Like the familiar Pearson correlation for continuous data, it is a symmetric measure, with range -1 « y « 1, where 1 indicates strong positive association and -1 indicates strong negative association. The gamma coefficient is defined by comparing the number of "concordant" pairs of observations to the number of "discordant" pairs. That is,
=
C-6 C + 6' significant associations occurring across domains. The proportion of significant within-domain associations is derived as the number of statistically significant associations for endpoints in the same domain divided by the number of all possible within-domain associations. A similar calculation is repeated for the associations across different domains. A higher percentage of significant within-domain associations would provide evidence of the existence of domains.
Factor analysis. Factor analysis is another standard technique used extensively in psychometric studies and other applications to summarize covariation and to determine how endpoints tend to group together, forming some underlying structure common to the observed variables (see, e.g., Morrison, 1990) . The variables composing this structure are termed factors. This type of analysis seems sensible in the present context since it can be hypothesized that FOB responses may correspond to observable manifestations of a few latent factor variables, possibly one factor variable for each neurophysiologic domain.
The basic concept behind factor analysis is that for each animal the vector of p observable variables, X, can be represented as a product of loading coefficients, L, times a set of m (presumed less than p) common factor variables, F, plus independent random errors. That is,
where fi is a vector of variable means. The components of L, the factor loadings, represent the relative strength of the factors' relation to each of the variables. The common factors F have zero mean and, in our model, are assumed to be uncorrelated with each other. The covariance matrix of X, Z, is related to the factor model by cov(X) = I = LL' + *, where t is the observed number of concordant pairs and t> is the number of discordant pairs. Concordant pairs occur when both variables for one endpoint are ranked higher than both observations from another endpoint. Discordant pairs occur when one of the variables in the pair is constant or decreases while the other variable increases. Ties between variables in the pairs are not counted in the y calculation. This definition is invariant to the actual numerical values given to the variables, making y a robust measure. Thus, for any two endpoints, the interpretation for a positive association is that when one endpoint is affected then the second endpoint is also. Note that y = 1 implies monotonicity of the variables but not strict monotonicity as it does with the Pearson correlation.
The extent of domain groupings was then measured by comparing the proportion of significant within-domain associations to the proportion of where * is die diagonal variance matrix of e. The essence of these calculations assumes that each measured outcome, say arousal, can be expressed as a linear combination of, say six unobserved quantities, f,, .. . ,/s, i.e., arousal = /,/, + / 2 / 2 + where the coefficients or factor loadings /|, . . . , / 6 gauge the degree of importance of each factor,/,, in determining the observable arousal quantity.
Factor analysis therefore combines observable variables into uncorrelated variables, called factors, in order to capture the greatest overall variability. Factors are independent, and can be considered separate "dimensions" in the space of observed responses. In our analysis, factors were initially determined using principal components analysis. This method chooses factors that explain the largest portion of overall variance based on the inherent correlations in the data. We set the maximum number of components at six, corresponding to the number of potentially distinct domains that have been identified as being physiologically important (Moser, 1992) . If fewer components explain the overall variance, then a smaller number of factors will emerge in the factor analysis. The factors were then rotated using the varimax criterion, maintaining the independence between factors, in order to more clearly delineate which endpoints belong to which factors (that is, the varimax procedure more clearly identifies factor loadings to be near 0 or 1). While other options for rotation are available, for example an oblique rotation (such as promax) which assumes correlation between the factors, these alternative methods gave similar results to the varimax rotation in our analysis, suggesting that the grouping of endpoints into factors was relatively insensitive to the assumption of independence or orthogonality of factors. Therefore, the varimax rotation is presented in this analysis. The analysis was carried out using the STATA software package (Stata Corporation, 1994) .
While methods for factor analysis designed specifically for ordered categories exist, they are not widely available. We therefore performed a standard factor analysis using the severity score scale which, after adjustment for pretreatment values, approximates a continuous distribution. One limitation of this approach, of course, is that the severity scores must represent interpretable quantities, an issue that is more tied to the basic construction of the scoring than to the choice of analysis.
Our goal was to compare the statistically derived factors with the Moser (1992) defined physiologic domain groups. Matches would lend evidence toward the domain structure.
Dose-response trend analysis. This portion of the study addressed whether the proposed domain structure is sensitive to identifying doserelated neurologic effects. That is, we assessed the degree to which analysis of the neurophysiologically based domain scores can detect dose-related trends in each of the domains. Inherent in this analysis was an investigation of the cost (in terms of missing potentially important dose-response trends) of grouping endpoints incorrectly. Endpoints with factor loadings equal to or greater than 50% of the highest factor loading in that factor. * Total variance accounted for by first six factors. ' Percentage of common variance captured by the individual factor. * This endpoint had a negative association with the other endpoints in this factor.
To accomplish this, we used 4-hr pretreatment adjusted data from each of the 10 studies. For each compound, domain severity scores were calculated using the 22 individual endpoints and a test for linear dose-response trend was conducted in each of the domains yielding, for each chemical, a set of six test statistics. The trend test statistics were corrected for the six multiple tests using Bonferroni correction (that is, p values were considered significant at the 0.05/6 = 0.0083 level). In order to evaluate the trend statistics, we compared the results to the expected theoretical domains of activity for each compound. As this is not a completely objective measure of the ability of the scoring system to identify effects (especially when there are individual endpoints with significant dose-response trends), we also compared the observed test statistics to those resulting from random regroupings of the endpoints into "pseudo-domains."
The reorganizations of the data had the same underlying structure as the Moser defined domains, in that the endpoints were divided into mutually exclusive sets with the same number of endpoints in each of the six neurological domains as defined by Moser (1992) (Table 1) . For each chemical, 1000 random samples were taken from all possible combinations of endpoint groupings within the six domains. A test for trend from a standard linear regression model was conducted on each pseudo-domain, and the distribution of these trend tests was established. These distributions are an approximation of the true randomization distribution of the set of six domain trend test statistics and therefore provide a basis for comparison to the actual set of trend tests defined by the Moser domain groupings. If the Moser domain groupings are neurophysiologically sound, they should provide trend tests that are more sensitive to detecting affected domains than those tests from pseudo-domains generated purely at random. To examine this, we compared the trend test statistics calculated for the neurophysiologically derived domain groupings to the randomly generated distributions.
This method looks globally across all animals, doses, and endpoints and was used to determine whether the particular domain structure chosen by Moser (1992) provides, in some sense, an "optimal" subgrouping of the 22 endpoints to detect domain effects. Test statistics that fall in the tails of the random distributions provide evidence that the Moser grouping scheme is performing well in identifying domain-level effects. For validity in identifying chemical neurotoxicity, statistically significant domains should match those domains that would be expected to be affected. To determine if the domains identified by this method as significantly affected matched expectation, they were compared to neurotoxic effects reported in the literature for exposed humans ( Table 2 ). The neurophysiologic domains that were associated with the observed human effects were rated on a scale of 0 (-) to 3 plus (+ ++) as those domains expected to be affected during acute exposures. This technique provides an assessment of the relative strength of the chosen domain structure, given the observed data on the 22 individual outcomes.
RESULTS
One strength of this analysis lies in the fact that the conclusions are based on the results from 10 chemicals. For the sake of brevity, we only illustrate in detail the results of chlordane at 4 hr and present the results of the other chemicals in summary tables. Both the 4-and 24-hr data yielded similar results; therefore, the 4-hr time point was selected for presentation because it is assumed to be closer to the time of peak effect and is thus more readily interpretable for acute effects. Detailed results for the other 9 chemicals are available upon request (TPH Technical Report, 1996) .
Bivariate Association Results
To illustrate the general results, the gamma association structure of the endpoints, adjusted for pretreatment values, are grouped by domain for chlordane in Table 4 , where gamma values are shown in matrix form for all pairs of endpoints (statistically significant associations are marked with an asterisk). Note that within the activity domain, posture is significantly associated with rears, an endpoint in the same neurophysiologic domain. In addition, posture also has significant associations with endpoints in other domains, such as the gait in the neuromuscular domain and defecation in the autonomic domain. Other endpoints have associations both within and across domains, and therefore within-domain association as distinct from associations across domains is not immediately obvious.
For example, the chlordane data show an equivalent percentage of statistically significant within-domain (29%) and across-domain (29%) associations, providing little statistical support for the presence of neurophysiologic domains. Table 5 shows the summary measures for all 10 chemicals. The results are similar to those for chlordane, with all chemicals having a roughly equivalent number of associations occurring within and across domains for both the 4-and 24-hr data. For some chemicals, the individual animal responses for the endpoints show a slightly higher degree of association among within-domain endpoints. However, looking across the 10 chemicals there is little evidence that association within domains tends to be stronger than that across domains providing little statistical support for the presence of neurophysiologic domains. Also, since the significant within-domain associations are not numerically near 1 (i.e., perfect association), these results indicate that there is not much redundant information among endpoints forming a particular domain.
Factor Analysis Results
In this analysis, endpoints are divided into factors based on groupings that provide statistically optimal subsetting of Linear trend tesl statistic the data (i.e., largest overall variance explained). Because factor analysis is designed to find the combination of variables that accounts for the greatest variability, the endpoints that are most correlated are expected in the few first factors. Thus, if the endpoints naturally form into neurophysiologic domains, the analysis should reveal this with the endpoints from each domain forming separate factors or at least grouping into the same factors.
To illustrate this approach, we will again present detailed results for chlordane where the distribution of endpoints across the six factors is shown (Table 6 ). Detailed results for the other nine chemicals are available upon request (IPH, 1996) . Table 6 shows no strong separation of endpoints into factors based on their neurophysiologic domain assignment. As indicated by the percentages of common variance across the six factors, no single factor accounted for a great amount of the variability in the data. For example, in the autonomic domain the four endpoints occur in three different factors, with only two endpoints, urination and pupil response, grouping within a single factor. However, the three endpoints of the activity domain group into two factors, with posture and rears comprising two of the five endpoints present in the second factor and counts in the third factor. While the activity domain results provide some evidence for endpoints within the same neurophysiologic domain grouping into the same factor, the orientation of the factors did not suggest a clear breakout of the endpoints into the theoretical domains (a result consistent with the bivariate gamma associations described above). One explanation for these results is that the low number of animals compared to number of endpoints (variables) may decrease the ability to discern differences in variability; or, it may be that these results suggest diat endpoints provide nonredundant information about their respective domains. That is, these results suggest that the neurophysiologic domain structure may not fully explain all the variability in the data. Table 7 summarizes the factor analyses for all 10 chemicals. The table shows endpoints grouped by neurophysiologic domain, where two or more endpoints from the same neurophysiologic domain grouped within a single factor. Endpoints from a neurophysiologic domain occurring in a factor without another endpoint from that domain are not included. Endpoints from a particular neurophysiologic domain may have been grouped into multiple factors, as in triadimefon, where there are three sets of endpoints from the neuromuscular domain indicating that the endpoints loaded together, but into three separate factors. Looking across all chemicals, within a domain there is little consistent overlap between outcomes. Overall, the endpoints of the neuromuscular and autonomic domains seem more likely to form statistical factors (they have the greatest number of endpoints composing their domains), followed by the endpoints of the activity, sensorimotor, and excitability domains. In general, as seen with chlordane, the results of the remaining 9 chemicals summarized in Table 7 provide no strong statistical evidence of grouping of endpoints into factors by neurologic domain. However, as shown in the next section, these results do not necessarily refute the validity of the concept of grouping endpoints by domains in testing for effects of exposure.
Dose-Response Trend Analysis Results
The preceding results suggest that although there are some strong correlation patterns in the data there is not a strong domain-oriented structure. However, the question remains whether the chosen domain structure is sensitive to identifying dose-response patterns within each domain. If the neurologically derived domains are able to detect significant effects, then an analysis based on the neurologically derived domain scores should be better at discriminating between positive and negative effects than any other grouping of the endpoints. There are many reasons why this might occur. For example, if effects in individual animals manifest in some endpoints of an affected domain in one animal but in other endpoints in other animals, then there will be little statistical correlation among endpoints in that domain (or even negative correlation), but tests of dose-response may still benefit from the domain averaging of endpoints. The results of this investigation are shown for chlordane in Fig.  1 , where histograms show the frequency distribution of linear trend test statistics (measuring the statistical linear association between dose and the domain scores) calculated from 1000 randomly drawn pseudo-domains based on regrouping the individual endpoint data. Each distribution represents one neurologic domain and all domains represent mutually exclusive regrouping of the endpoints. The position of the trend test statistic from the neurologic domain groupings defined by Moser in relation to the randomly derived pseudodomain is shown by the vertical line in each distribution. An asterisk indicates a statistically significant domain trend test after accounting for the six multiple tests (using Bonferroni correction, a trend test statistic of ±2.638 would be considered significant at the overall 5% level). Trend test scores near 0 might be interpreted as a lack of response for that domain or a "true" unaffected domain.
As shown in Fig. 1 , for chlordane the Moser-defined excitability domain has a significant trend test value of 3.97, placing it in the upper tail of the distribution with 89.4% of the random distribution trend test values (in absolute value) falling below it. This indicates that the random pseudo-domain grouping of endpoints had a higher trend test value than the neurophysiologic excitability domain in only 10.6% of the 1000 samples. Therefore, the endpoints that make up the excitability domain (arousal, removal, and handling) appear to be providing some degree of statistical power in describing the activity seen in this domain. The other neurophysiologic domain test scores fall toward the middle of their respective random distributions for chlordane, indicating that these domains fared no better than that expected by groupings determined solely by chance assignment of outcomes to domains. In the nonsignificant sensorimotor domain, only 2.3% of the distribution falls within the range of the absolute value of the trend test statistic of 0.15, suggesting that no effects of chlordane manifested themselves in the sensorimotor domain. In other words, a random pseudo-domain trend test score closer to 0 occurred only 2.3% of the time, indicating that the neurophysiologic domain grouping of the endpoints thought to represent the sensorimotor domain was better at describing a lack of effect than 97.7% of the random groupings. If these data represent the "true" effects of chlordane, then the chosen domain structure provides evidence of a domain of effect, excitability, and a domain without demonstrated effect, sensorimotor. The results of this analysis are reasonable in that the neurologic domain grouping identified an expected effect in the excitability domain and showed little effect in the sensorimotor domain, which is consistent with current toxicologic understanding of this chemical (see Table 2 ). Table 2 lists acute effects reported in the literature for each chemical, which were then associated with a domain. Because the number of effects and the severity of effects increase with dose, the domains of expected effects were assigned scores ranging from " + + + " for most likely to be affected at low doses, to "-" for unlikely to be affected. If the neurologically derived domains are able to detect significant domain effects, then the trend tests for the affected (i.e., biologically significant) neurologic domains should be statistically significant and in the upper tail of the distributions of randomly generated pseudo-domain trend tests. Similarly, unaffected (i.e., not biologically significant) domains should have trend test statistics near 0. That is, the assay should be able to discriminate well between affected and unaffected domains. The bar graphs in Fig. 2 summarize the trend test distributions for the 10 chemicals studied. The upper portion of each panel (positive percentages) reports the percentage of the random domain trend test distribution falling within the absolute value of the trend test statistic for the neurologically derived domains expected to be biologically significant and indicates how well these neurophysiologic domains performed compared to the random groupings of endpoints. Neurophysiologic domains with statistically significant trend test scores are indicated by an asterisk. For example, the excitability and activity domains are expected to be affected by treatment with Heptachlor (Table  2 ) and the trend test was better at describing the effects than 98 and 93%, respectively, of the random groupings. In addition, the trend tests of the data were statistically significant for both domains, suggesting that both the excitability and the activity domains are affected by Heptachlor and that the neurophysiologic domain groupings are able to detect the expected effects.
A similar strategy can be applied to the nonbiologically significant domains to assess the ability of the domain grouping to give information about domains not affected by the test agent. The bars for the domains not expected to be affected Gower half of each panel in Fig. 2 , "negative" percentages) again represent the percentage of the random domains falling within the absolute value of the trend test statistic, indicating the likelihood that another grouping of the endpoints would yield a value closer to 0 compared to the trend test value from the endpoints grouped by neurophysiologic domain. The smaller the percentage reported in the bar graphs, the less likely it is that another grouping of endpoints into that domain would have even less evidence of a dose-response trend. When the percentage of the statistically significant domain distribution captured by the neurophysiologic domain is close to 50%, e.g., the activity domain for perchloroethylene, it suggests that the neurophysiologic domain is not able to discriminate better than a random grouping of the endpoints. However, this could also occur because a large number of individual endpoints were significantly affected by exposure so that any grouping of the endpoints into domains would give a statistically significant result. Even though statistical power issues make it impossible to determine the true negative rate in these data, this method suggests that when the randomization results are compared to information in the literature about expected domains of effect and no effect, the neurophysiologic do-FIG. 2. Comparison of neurologically derived domains' ability to detect significant domain effects to that of randomly generated domains. Bars show the percentage of the random domain trend test statistic distribution falling within the absolute value of the trend test statistic for the neurologically derived domain grouping, where asterisks indicate a significant neurologically derived domain trend test statistic after accounting for multiplicity (p < 0.05/6 = 0.0083). Domains expected to be affected are indicated in the upper portion of each panel (positive percentages), while the lower portions of the panels (negative percentages) indicate domains not expected to be affected. Expected and unexpected affected domains were derived from the toxicologic literature summarized for each chemical in Table 2 . Bars at 50% suggest that the neurophysiologic domain is not able to discriminate better than a random grouping of endpoints. An increase in bar size suggests that the neurophysiologic domains are better at describing the effects than the random domain groupings. For bars less than 50%, the smaller the bar, the less likely it is that another grouping would have less evidence of a doseresponse trend. main groupings appear able to discriminate between domains of effect and no effect. As seen in Fig. 2 , the percentage of the random distribution captured by the neurologic domain grouping varies from chemical to chemical. Generally, in domains that are expected to be affected by the chemical, the neurologic domains tend to perform better than groupings based on random selection of endpoints. These results provide some evidence that the neurologic domain groupings are reasonably sensitive to identifying expected exposure related effects.
Influence of Highest Dose Level
At the highest tested dose, a large number of individual endpoints were found to be significantly affected by exposure to the solvents tested and many of the statistically significant trend test values did not capture a high percentage of the random domain trend test distribution (Fig. 2C) . Concerned that the highest dose was overly influencing the trend test statistics, we repeated the randomization analysis after removing the data for this dose level. As Fig. 3 shows, the effects were most dramatic for the solvents (Fig. 3C) , as anticipated from the first analysis, while the pesticides (Fig.  3A) were least affected. The doses selected for the chemicals in this neurotoxicity screening battery were fixed percentages of the LD50, although three out of four solvents were tested at the limit dose. After the highest dose was removed, the number of significant endpoints found for the solvents was dramatically reduced, leaving only the neuromuscular domain for perchloroethylene and the sensorimotor domain for trichloroethylene as significantly affected domains. However, for the pesticides, most domains that were significant and expected with all doses remained significant after removal of the highest dose. Therefore, removing the highest dose for agents with many effects may help identify neurospecific effects that are distinct from general toxicity.
DISCUSSION
We investigated the statistical properties of an FOB data scoring algorithm and its relation to neurophysiologic-derived domains as described by Moser (1992) . Our results suggest that although there is not substantial evidence of within-domain association among the endpoints, testing significance of FOB effects at the domain level may still be an effective and powerful method to detect effects while controlling the overall type I error rate that could be substantial in an analysis of individual endpoints. Given the large number of endpoints in the FOB, statistical concerns include redundancy of information, multiplicity or false positives, and the proper grouping of endpoints to be sensitive to detecting effects. The bivariate association and factor analysis results showed that each endpoint appears to provide relatively independent information about a chemical's neuroactive properties, with only weak domain-level associations in the data; thus there was little redundant information. The dose-response trend analysis, however, provides evidence that the neurologic domains are sensitive to identifying expected exposure-related neurologic effects. In addition, grouping endpoints into domains provides a means to investigate the presence of a profile of effects that may be more biologically plausible and statistically sensitive than identifying a single critical effect for the identification of a neurotoxic agent. This issue is intimately tied to whether the FOB is used only to screen (where type I errors are less of a concern) or as the definitive evaluation of a chemical for regulatory purposes (more concern about type I error). Thus, grouping by domains followed by individual endpoint analysis in significant domains and correcting for multiplicity at both levels may be the best strategy for hazard identification.
Another concern of a neurotoxicity screening assay is that the effects observed will not reflect specific neurotoxicity, but instead will represent neurologic/behavioral carry-over of general toxicity. This is because the large number of endpoints coupled with diffuse presentation of effects can make it difficult to discern true neurotoxic events from nonspecific effects. This issue appeared to occur in our evaluation for the chemicals in the solvent group (see Fig. 2 ). The dose-response trend test analysis showed statistically significant trends for most domains when all doses were analyzed; however, most randomly derived pseudo-domains also showed statistically significant dose-related trends, suggesting lack of specificity of effects. This could also be the result of poor discrimination of the trend test when most endpoints are univariately significant, resulting in pseudodomains that are all statistically significant regardless of the randomization. When the highest dose was removed from the analysis, there were fewer neurophysiologic domains with statistically significant trend tests, they tended to be in the upper tail of the pseudo-domain trend test score distribution, and furthermore, the significant domains were those expected to be affected (see Fig. 3 ). These results suggest that the high doses used to ensure induction of toxicity can also lead to nonspecific effects in the FOB, but that a method such as the dose-response trend analysis can help identify FIG. 3 . Comparison of neurologically derived domains' ability to detect significant domain effects to that of randomly generated domains: Chemicals with highest dose excluded. Bars report the percentage of the random domain trend test statistic distribution falling within the absolute value of the trend test statistic for the neurologically derived domain grouping, where asterisks indicate a significant trend test statistic after accounting for multiplicity (p < 0.05/6 = 0.0083). The upper portion of each panel (positive percentages) indicates domains expected to be affected, while the lower portions of the panels (negative percentages) indicate domains not expected to be affected. The interpretation of the bars is the same as in the legend to Fig. 2. when nonneurotoxic specific effects are occurring. When the highest doses for the chemicals in the pesticide group were removed from the analysis, the majority of the neurophysiologic domains expected to be affected remained significant and continued to score better than the pseudo-domains. The stability in response suggests that the effects observed at the domain level were related to neurotoxic-specific effects.
The small number of animals per dose group may limit the ability of this analysis to measure association among the endpoints. Therefore we may have decreased power to detect effects given the large number of variables and relatively few observations. Further simulation-based studies of the small sample properties of the method would also be useful. While our use of FOB data here has certain advantages, issues of power and type I error of the method are not directly addressable. A similar analysis using simulated data would allow direct assessment of these properties, but a reasonable multivariate model would have to be constructed to generate the data. Simulations could also be used to investigate the properties of other multiple comparison methods and to more directly assess the impact of various correlation structures on the domain scoring approach.
This analysis used a set of 10 chemicals studied with identical protocols as its basis (Moser et al., 1995) ; however, they were not selected for their neurotoxic properties. Future analyses could be strengthened by using chemicals with known mechanisms and distinct neurotoxicity profiles.
Several issues pertaining to the analysis of the FOB remain unexplored. For example, the analysis of multiple event data remains a statistical challenge. The method proposed by Moser simplifies a complex set of multivariate endpoints to a simpler set of six scores. Assuming that the neurophysiologic domain model is appropriate, the technical question of how to best create the scores needs further attention, as there are more sophisticated alternatives to simply summing the individual severity scores. For example, one might consider models that allow for weighting the individual responses, factor analytic models that formally exploit the underlying correlation structure from the individual endpoint scores, or more theoretically motivated models based on latent variables. All of these issues need exploration.
Another difficult statistical issue lies in analyzing effects over time. For acute neurotoxicity testing, the FOB is usually performed before treatment, near the time of peak effect, and 24 hr after treatment. We focused our analysis on the 4-hr data, assuming that it approximated the time of peak effect and was the most likely to represent the true neurotoxic effects; however, the 24-hr data contain information about neurotoxicity and relate to the overall toxicity information for any chemical. The profile of effects evaluated over time may be even more important in subchronic studies. Ideally a flexible analysis method would include all effects at all times measured; however, it is currently difficult to evaluate effects in both the time and multiple effects dimensions.
Methods to improve interpretation of multivariate data are needed and currently under development in other areas of noncancer hazard identification, such as developmental toxicity (Catalano et al, 1993) .
New strategies for evaluation, such as the transformation of responses that include continuous, dichotomous, categorical, count, and observational data to a standard severity score and the grouping of endpoints into neurophysiologic domains as proposed by Moser (1992) , are designed to allow for greater quantitative assessment of the data. In addition to increasing statistical efficiency and control of false positives, grouping the endpoints into domains would allow for the analysis of a profile of more generalizable neurologic effects. Identification of domain profiles would inform the risk assessor about where to focus future studies or allow regulation on specific activity within a domain. This approach avoids putting too much emphasis on individual endpoints and aims to combine evidence into a relatively small array of neurologic categories. Based on our trend test results, this analysis suggests that there is a benefit to grouping the endpoints by domains, but the association analysis suggests that the proposed domains of Moser (1992) might not necessarily be the optimal grouping.
The manner in which the data will be used influences the selection of an optimal analytic method. Data used for screening purposes, where additional testing will be conducted, can be analyzed in a manner that permits more false positives than data that will be used to set regulatory levels. The Proposed Guidelines for Neurotoxicity Risk Assessment Notice (1995) suggest that results from the FOB assay could be used to set reference doses, provided that several related endpoints are affected in a dose-dependent manner in the absence of systemic toxicity. Analysis of the FOB data by domains could satisfy that requirement.
